Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTONASDAQ:AVRONASDAQ:CGTXNASDAQ:SNTI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.22-0.8%$1.57$1.20▼$8.70$19.33M1.2973,883 shs56,221 shsAVROAVROBIO$1.19-1.7%$1.28$0.57▼$1.70$54.28M1.22272,822 shs348,448 shsCGTXCognition Therapeutics$1.99-0.5%$1.93$0.90▼$3.49$77.61M1.63197,143 shs113,946 shsSNTISenti Biosciences$0.28-6.6%$0.38$0.27▼$1.10$12.85M2.96107,117 shs51,554 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences-0.81%-3.17%-19.21%-36.13%-83.06%AVROAVROBIO-1.65%-2.46%-2.46%-9.85%+34.46%CGTXCognition Therapeutics-0.50%+4.74%+9.34%-12.33%+12.43%SNTISenti Biosciences-6.05%-9.39%-31.15%-31.57%-72.73%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTOAptose Biosciences1.146 of 5 stars3.53.00.00.00.60.00.6AVROAVROBIO1.0438 of 5 stars3.03.00.00.00.01.70.6CGTXCognition Therapeutics3.5143 of 5 stars3.55.00.00.03.24.20.0SNTISenti Biosciences2.4657 of 5 stars3.54.00.00.02.60.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences3.00Buy$19.801,522.95% UpsideAVROAVROBIO2.00Hold$2.0068.07% UpsideCGTXCognition Therapeutics3.00Buy$6.67235.01% UpsideSNTISenti Biosciences3.00Buy$6.002,035.99% UpsideCurrent Analyst RatingsLatest APTO, CGTX, AVRO, and SNTI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$5.003/28/2024CGTXCognition TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/27/2024APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.003/27/2024CGTXCognition TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.002/1/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $5.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AAVROAVROBION/AN/A$0.28 per share4.19$2.13 per shareN/ACGTXCognition TherapeuticsN/AN/AN/AN/A$0.76 per shareN/ASNTISenti Biosciences$2.56M5.02N/AN/A$1.50 per share0.19Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$7.72N/AN/AN/AN/A-458.70%-205.30%5/13/2024 (Estimated)AVROAVROBIO$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%5/9/2024 (Estimated)CGTXCognition Therapeutics-$25.79M-$0.86N/AN/AN/AN/A-83.48%-63.07%5/2/2024 (Estimated)SNTISenti Biosciences-$71.06M-$1.60N/A∞N/A-2,692.82%-74.59%-48.22%5/14/2024 (Estimated)Latest APTO, CGTX, AVRO, and SNTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023APTOAptose Biosciences-$1.48-$1.44+$0.04-$1.44N/AN/A3/26/2024Q4 2023CGTXCognition Therapeutics-$0.38-$0.27+$0.11-$0.27N/AN/A3/21/2024Q4 2023SNTISenti BiosciencesN/A-$0.42-$0.42-$0.42N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A0.780.78AVROAVROBION/A15.7815.78CGTXCognition TherapeuticsN/A3.373.37SNTISenti BiosciencesN/A5.625.62OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%AVROAVROBIO62.63%CGTXCognition Therapeutics43.35%SNTISenti Biosciences25.73%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences9.53%AVROAVROBIO9.20%CGTXCognition Therapeutics23.80%SNTISenti Biosciences12.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences3115.72 million14.22 millionNo DataAVROAVROBIO1344.86 million40.73 millionOptionableCGTXCognition Therapeutics2539.00 million29.72 millionNot OptionableSNTISenti Biosciences4845.76 million40.04 millionNot OptionableAPTO, CGTX, AVRO, and SNTI HeadlinesSourceHeadlineSenti Biosciences (NASDAQ:SNTI) Shares Down 8.7% americanbankingnews.com - April 23 at 3:00 AMSenti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlightsfinanznachrichten.de - March 23 at 5:22 PMSenti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlightsglobenewswire.com - March 21 at 4:05 PMSenti Biosciences Stock (NASDAQ:SNTI), Guidance and Forecastbenzinga.com - February 4 at 7:36 PMSenti Biosciences, Inc.: Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Programfinanznachrichten.de - January 8 at 7:36 AMSenti Biosciences to Cut Workforce by 37% to Focus on Potential Cancer Treatmentmarketwatch.com - January 5 at 8:33 PMSenti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Programfinance.yahoo.com - January 5 at 8:33 PMWhy Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?finance.yahoo.com - December 22 at 12:31 PMSenti Bio : FDA Clears IND Application For SENTI-202 For Treatment Of R/R Hematologic Malignanciesmarkets.businessinsider.com - December 22 at 7:31 AMSenti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemiafinance.yahoo.com - December 22 at 7:31 AMSenti Biosciences, Inc.: Senti Bio Announces Third Quarter 2023 Results and Pipeline Updatesfinanznachrichten.de - November 24 at 8:31 AMSenti Bio Announces Third Quarter 2023 Results and Pipeline Updatesfinance.yahoo.com - November 13 at 5:04 PMSenti Biosciences Inc SNTImorningstar.com - November 11 at 1:25 PMSenti, Celest take liver cancer cell therapy to China in $156M biobucks dealfiercebiotech.com - November 9 at 6:36 PMOff-the-shelf CAR-NK cell therapy to be developed in Chinathepharmaletter.com - November 9 at 1:36 PMRecent Insider Activity Could Benefit Senti Biosciences Inc. (SNTI)knoxdaily.com - November 8 at 8:13 PMWhy Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?msn.com - November 7 at 1:54 PMWhy Is Ventyx Biosciences (VTYX) Stock Down 76% Today?msn.com - November 7 at 8:53 AMWhy Is Senti Biosciences (SNTI) Stock Up 140% Today?msn.com - November 7 at 8:53 AMSenti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in Chinafinance.yahoo.com - November 6 at 7:39 PMSenti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meetingfinance.yahoo.com - October 31 at 1:59 PMGene and cell therapy startup GeneFab takes over Senti Biosciences' Alameda manufacturing facilitybizjournals.com - October 9 at 8:46 PMTaking a look at what insiders are doing to gauge the Senti Biosciences Inc. (SNTI)’s directionknoxdaily.com - October 5 at 3:22 PMShanti Overseas India Ltd (SNTI)investing.com - September 27 at 6:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptose BiosciencesNASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.AVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Cognition TherapeuticsNASDAQ:CGTXCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.Senti BiosciencesNASDAQ:SNTISenti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.